Specific Changes:

1) Expand the BRCA1/2 testing criteria to include all patients with a personal diagnosis of pancreatic cancer.

2) Add the following footnote to the new “Personal history of pancreatic cancer” testing criteria
   • Due to the link between pancreatic cancer and multiple additional genes (i.e., ATM, PALB2, CDKN2A, MLH1, MSH2) implicated in hereditary cancer syndromes, testing with a multigene panel should be strongly considered as an alternative to BRCA1/2 testing alone.

FDA Clearance: Not applicable.

Rationale: Multiple recent studies have demonstrated high positive rates for hereditary cancer genes (including BRCA1/2) in patients with a personal history of pancreatic cancer regardless of age and family history.

The following articles are submitted in support of this proposed change. We would like to acknowledge the contributions of NCCN panel members who are also co-authors or co-contributors of some of these publications.


Sincerely,

Johnathan Lancaster, MD, PhD
Chief Medical Officer
Myriad Genetic Laboratories Inc.